comparemela.com

Page 5 - Diabetes Therapy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Liquid Diet For Weight Loss: Benefits, Types & Risks In 2023

SGLT2 inhibitor luseogliflozin bests DPP4 inhibitors among diabetes patients

Japan: A recent study published in Diabetes Therapy has shown the efficacy of luseogliflozin (SGLT2 inhibitor) over DPP-4 inhibitors in the mid/long-term, irrespective of BMI or age.The study revealed.

vimarsana © 2020. All Rights Reserved.